Dr. Armen Aprikian is the Clinical Lead of McGill’s Rossy Cancer Network and is President-elect of the Canadian Urology Association.
Dr. Armen Aprikian graduated from the University of Sherbrooke Medical School in Quebec in 1985 and completed his urology residency training at McGill University in 1990. He then pursued a 3-year research and clinical fellowship in urologic oncology at Memorial Sloan Kettering Cancer Centre in New York City. In 1993 he was appointed Assistant Professor of Surgery (Urology) at McGill University and began his career in prostate and bladder cancer research and as a clinical urologic oncologist. In 1998 he became the McGill Division of Urology Training Program Director and in 2000 established the Annual Canadian Senior Resident Urologic Oncology Course which runs to this day. In 2004 he became the Head of the Division of Urology at McGill University and the Chief of Urology at the McGill University Health Centre (MUHC). In 2007 he became Full Professor of Surgery and Oncology and in 2009 he was appointed the Medical Director of the MUHC Cancer Care Mission and Chief of the Department of Oncology. Moreover, in 2010 he was appointed the McGill University Richard Tomlinson Professor in Prostate Cancer. Finally, in 2020 he was appointed as Clinical Lead of McGill’s Rossy Cancer Network.
Dr. Aprikian has been awarded the American Society of Clinical Oncology Young Investigator Award, the American Urologic Association Practicing Urologist Award, the Canadian Urology Association Scholarship, the McGill University William Dawson Scholar Career Award and the Quebec FRSQ Senior Clinician Scientist Award. He has obtained independent peer-reviewed grants from several organizations including the US Department of Defense and the National Cancer Institute, and served as interim editor in chief of the Canadian Urology Association Journal. In addition, in 2004 he was a founding member of Procure, a Quebec-based Prostate Cancer Foundation dedicated to research and public awareness. He serves or has served on several Boards of Directors or executive committees, including the Rossy Cancer Network of McGill University, Cedars Cancer Foundation, Goodman Cancer Research Centre, MUHC-Research Institute, Canadian Urology Association, Bladder Cancer Canada, and Procure Alliance. He is a member of the Mashdots Foundation executive committee and serves as a reviewer for the Semerdjian Fund. He is actively involved in a leadership role in national and provincial guidelines in prostate, bladder and testicular cancer surgery outcomes and has published over 230 peer-reviewed original scientific papers. Finally, he was nominated as President-elect of the Canadian Urology Association.